Mitoxantrone-Induced Bradycardia
Authors: Mustafa Benekli
Journal: Annals of Internal Medicine (1997)

Letters1 March 1997Mitoxantrone-Induced BradycardiaMustafa Benekli, MD, Ayse Kars, MD, and Nilufer Guler, MDMustafa Benekli, MDHacettepe University Institute of Oncology, Ankara, Turkey, Ayse Kars, MDHacettepe University Institute of Oncology, Ankara, Turkey, and Nilufer Guler, MDHacettepe University Institute of Oncology, Ankara, TurkeyAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-5-199703010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Anthracycline-induced cardiotoxicity was well described by Shan and associates [1]. Mitoxantrone is a dihydroxyanthracenedione derivative that seems to be an effective and better-tolerated alternative to the anthracycline component of standard regimens for most hematologic cancer [2]. We report sinus bradycardia in two patients who had acute lymphoblastic leukemia after mitoxantrone treatment. This is, to our knowledge, the second report of mitoxantrone-induced bradycardia [3].Patient 1 was a 36-year-old, previously healthy man who presented with neutropenic fever; empirical amikacin and ceftazidime therapies were started. Physical examination was remarkable only for a temperature of 39 °C. Blood pressure was ...References1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996; 125:47-58. Google Scholar2. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs. 1991; 41:400-49. Google Scholar3. Umemoto M, Kawasaki H, Azuma E, Komada Y, Ito M, Sakurai M. Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy. Am J Hematol. 1996; 52:327-8. Google Scholar4. Bethell H, Grace AA, Hall JA, Petch MC, Schofield PM. Bradycardia due to anthracyclines. Lancet. 1992; 340:858. Google Scholar Author, Article, and Disclosure InformationAffiliations: Hacettepe University Institute of Oncology, Ankara, Turkey PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAntineoplastic drug-induced bradyarrhythmiasSynthesis and Antitumor Evaluation of Bis Aza-anthracene-9,10-diones and Bis Aza-anthrapyrazole-6-onesAnthracycline cardiotoxicityDesign and synthesis of novel amino-substituted xanthenones and benzo[b]xanthenones: Evaluation of their antiproliferative activity and their ability to overcome multidrug resistance toward MES-SA/D×5 cellsDesign, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cellsSynthesis and cytotoxic activity of some new azapyranoxanthenone aminoderivativesBbr 2778, an Aza-anthracenedione Endowed with Preclinical Anticancer Activity and Lack of Delayed CardiotoxicityMitoxantrone-induced cardiotoxicitySynthesis and Antitumor Evaluation of 2,5-Disubstituted- Indazolo[4,3- gh ]isoquinolin-6(2 H )-ones (9-Aza-anthrapyrazoles)Mitoxantrone 1 March 1997Volume 126, Issue 5Page: 409KeywordsBlood pressureBradycardiaChemotherapyElectrocardiographyFeversHeart ratePrecursor cellsTemperatureToxicityTransferases Issue Published: 1 March 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...